Tepotinib/osimertinib combination induces ORR benefit in EGFR mutated non-small cell lung cancer

Tepotinib (Tepotinib) combined with Osimertinib (Osimertinib) is a promising combination for the treatment of osimertinib-pretreated, EGFR mutated, MET amplified non-small cell lung cancer (NSCLC) patients. He emphasized that further studies of MET amplification should be conducted to determine whether this biomarker can predict clinical benefit in certain patient subpopulations.

Issue 2INSIGHT 2 trial (NCT03940703) evaluated tepotinib plus osimertinib in this population and showed that the combination had an overall response rate (ORR) of 45.8% (95% CI, 31.4%-60.8%) in patients with MET amplification detected by fluorescence in situ hybridization (FISH) with at least 3 months of follow-up (n=48). The overall response rate of the combination was 54.5% (95% CI, 32.2%-75.6%) at 9 months, with an ORR of 8.3% (95% CI, 0.2%-38.5%) among patients with MET amplification detected by FISH who received tepotinib alone and were followed for at least 6 months (n=12).

The investigators also observed a favorable response to the combination in patients with MET amplification detected by next-generation sequencing, with an ORR of 3 months or more of follow-up (n=23) 56.5% (95% CI, 34.5%-76.8%), and the ORR was 50.0% (95% CI, 24.7%-75.3%) at 9 months or more follow-up (n=16).